Inhibition of vein graft intimal hyperplasia by periadventitial application of hyaluronic acid–carboxymethyl cellulose: An experimental study

Bahçivan, Muzaffer; Yücel, Semih Murat; Kefeli, Mehmet; Göl, M. Kamil; Can, Bilge; Keçeligil, Hasan Tahsin

doi:10.1080/14017430701747108

Cited by 9 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To investigate whether external support would reduce intimal hyperplasia at the site of venous graft anastamosis, rabbits undergoing bypass grafting of the right jugular vein to the right common carotid artery was performed in the presence or absence of wrapping the anastamosis with Seprafilm [67]. Evaluation at 1 month demonstrated that use of Seprafilm reduced both neointimal and medial thickening.…”

Section: Seprafilm Adhesion Barriermentioning

confidence: 99%

Seprafilm® adhesion barrier: (1) a review of preclinical, animal, and human investigational studies

et al. 2012

View full text Add to dashboard Cite

The aim of this study was to provide a single site resource for investigators, clinicians, and others seeking preclinical, animal, and human investigational studies concerning the postsurgical, anti-adhesion barrier Seprafilm™ (Genzyme Corporation, Cambridge, MA). All published preclinical, animal, human extra-abdominal research as of July 2011 have been summarized and included in this document. Searches of Medline and EMBASE Drugs and Pharmaceuticals databases were conducted for original preclinical, animal, and human extra-abdominal studies involving Seprafilm. Preclinical, animal, and extra-abdominal human investigational studies are the study selection for this manuscript. Intraabdominal use is discussed in the accompanying manuscript. Data extraction includes systematic manuscript review. Summary of preclinical, animal, and extra-abdominal human investigational use of Seprafilm by surgical discipline were gathered for data synthesis. The clinical use of Seprafilm, which was approved by the FDA for intra-abdominal procedures, is supported by preclinical and animal studies relating to general surgical and obstetrical/gynecological applications. Findings from preclinical, animal, and human investigational studies at other sites throughout the body raises the potential for additional human clinical trials to assess efficacy and safety following surgical procedures at non-abdominal locations.

show abstract

Section: Seprafilm Adhesion Barriermentioning

confidence: 99%

Seprafilm® adhesion barrier: (1) a review of preclinical, animal, and human investigational studies

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Bahcivan et al studied the effect of hyaluronic acidcarboxymethyl cellulose on neointimal hyperplasia experimentally. They claimed that HA prevents the development of neointimal hyperplasia on vein grafts through a positive effect on tissue repair due to its barrier-forming nature [18]. Thus, we studied the effects of a HA-based endothelial protection solution for vein grafts for the creation of AV fistulas.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness and safety of using a novel endothelial damage inhibitor in arteriovenous fistula formation

Khalil¹,

Akalın²

2019

Journal of Surgery and Medicine

View full text Add to dashboard Cite

Aim: Patients with end-stage renal disease need accurate and effective vascular access for hemodialysis. Although renal transplantation is the golden standard treatment that provides a life without hemodialysis, an arteriovenous (AV) fistula is the most frequent method for sustaining long-term hemodialysis because of insufficient renal donors. In the current study, we aimed to compare patency rates of AV fistulae created with or without the endothelial protection solution. Methods: This single-center case-control study was conducted between August 2018 and August 2019. Patients with end-stage renal disease requiring AV fistula access for hemodialysis (n=49) were included in the study and divided into two groups. During the creation of an AV fistulae, endothelial protection solution was used in 27 patients, who constituted Group A, and not used in 22 patients, who were included in Group B (the control group). All fistulae anastomoses were performed by the same surgical team. The demographical data, maturation time, mean flow volume, complications, basal metabolism index (BMI), and patency rates at the 3 rd and 6 th months were compared. Results: There was no significant difference between the two groups regarding demographical findings (p>0.05). The patency rates were higher in group A at both the 3 rd and 6 th months (96% and 93%) when compared with group B (64% and 27%) (P<0.05). Conclusion: AV fistulae created with endothelial protection solution has higher patency rates compared to conventionally created AV fistulae.

show abstract

“…Adventitial administration of gene transfer vectors and nanoparticles have also been studied to deliver platelet-derived endothelial cell growth factor (PD-ECGF) thymidine phosphorylase (TP) [39] and microRNA-145 (miR-145)loaded poly(lactic-co-glycolic acid) (PLGA) [40] to modulate SMC chemotaxis and phenotype from proliferative to contractile states. Fibrin sealants such as cyanoacrylate [41,42] , anti-adhesive agents such as hyaluronic acid-carboxymethyl cellulose (HA/CMC) [43] , and collagen cross-linking with photoactive tissue passivation [44] have also been investigated as methods of providing mechanical offloading to vein grafts without sheath implants. As with external vein graft stents, the long-term effects of these adventitial treatments remain to be seen and will remain a subject of future investigation.…”

Section: Modern Therapies To Prevent Vein Graft Failurementioning

confidence: 99%

The biomechanics and prevention of vein graft failure in coronary revascularization

Heng,

Wang,

Obafemi

et al. 2023

Vessel Plus

View full text Add to dashboard Cite

Saphenous vein grafts (SVGs) are the most widely used conduit in coronary artery bypass grafting (CABG) surgery; however, SVG failures due to neointimal hyperplasia present a significant long-term limitation to the effectiveness of myocardial revascularization. This review will provide a comprehensive overview of the biological mechanisms of vein graft failure, including compensatory endothelial proliferation, extracellular matrix deposition, and adventitial disruption. We will discuss historical and emerging strategies for vein graft failure prevention with a focus on the role of mechanical vein graft support using external stenting. Finally, we will highlight the results of preclinical and human trials and discuss future directions for investigation.

show abstract

Inhibition of vein graft intimal hyperplasia by periadventitial application of hyaluronic acid–carboxymethyl cellulose: An experimental study

Abstract: Periadventitial placement of HA/CMC as an absorbable membrane inhibits intimal hyperplasia of vein bypass grafts in a rabbit model.

Cited by 9 publications

References 11 publications

Seprafilm® adhesion barrier: (1) a review of preclinical, animal, and human investigational studies

Seprafilm® adhesion barrier: (1) a review of preclinical, animal, and human investigational studies

Effectiveness and safety of using a novel endothelial damage inhibitor in arteriovenous fistula formation

The biomechanics and prevention of vein graft failure in coronary revascularization

Contact Info

Product

Resources

About